IL-21: Roles in immunopathology and cancer therapy

Tissue Antigens

Volumn 74, Issue 6, 2009, Pages 467-479

  Sondergaard H ^a   Skak, K ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Autoimmunity; Cancer; Cytokine; Interleukin 21

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 7; INTERLEUKIN 9; RITUXIMAB; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; ENTERITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE TARGETING; HUMAN; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOID CELL; MACROPHAGE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYALGIA; NATURAL KILLER T CELL; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANIMALS; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; INTERLEUKINS; NEOPLASMS; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION;

EID: 70449334555     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2009.01382.x     Document Type: Review

References (88)

1. Ozaki K, Kikly K, Michalovich D et al. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 2000 : 97 : 11439 11444.
2. Parrish-Novak J, Dillon SR, Nelson A et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000 : 408 : 57 63.
3. Asao H, Okuyama C, Kumaki S et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001 : 167 : 1 5.
4. Zeng R, Spolski R, Casas E et al. The molecular basis of IL-21-mediated proliferation. Blood 2007 : 109 : 4135 4142.
5. Frederiksen KS, Lundsgaard D, Freeman JA et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008 : 57 : 1439 1449.
6. Caprioli F, Sarra M, Caruso R et al. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 2008 : 180 : 1800 1807.
7. Zeng R, Spolski R, Finkelstein SE et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005 : 201 : 139 148.
8. Coquet JM, Kyparissoudis K, Pellicci DG et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007 : 178 : 2827 2834.
9. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008 : 26 : 57 79.
10. Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006 : 55 : 1774 1780.
11. Kasaian MT, Whitters MJ, Carter LL et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002 : 16 : 559 569.
12. Ozaki K, Spolski R, Feng CG et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002 : 298 : 1630 1634.
13. Jin H, Carrio R, Yu A et al. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J Immunol 2004 : 173 : 657 665.
14. Good KL, Bryant VL, Tangye SG. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J Immunol 2006 : 177 : 5236 5247.
15. Konforte D, Simard N, Paige CJ. IL-21: an executor of B cell fate. J Immunol 2009 : 182 : 1781 1787.
16. Suto A, Nakajima H, Hirose K et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood 2002 : 100 : 4565 4573.
17. Wood N, Bourque K, Donaldson DD et al. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol 2004 : 231 : 133 145.
18. Pesce J, Kaviratne M, Ramalingam TR et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006 : 116 : 2044 2055.
19. Silver JS, Hunter CA. With a little help from their friends: interleukin-21, T cells, and B cells. Immunity 2008 : 29 : 7 9.
20. Wei L, Laurence A, Elias KM et al. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 2007 : 282 : 34605 34610.
21. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007 : 178 : 732 739.
22. Ferrari-Lacraz S, Chicheportiche R, Schneiter G et al. IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes. Int Immunol 2008 : 20 : 1009 1018.
23. Wuest TY, Willette-Brown J, Durum SK et al. The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol 2008 : 84 : 973 980.
24. Nurieva R, Yang XO, Martinez G et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007 : 448 : 480 483.
25. Korn T, Bettelli E, Oukka M et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009 : 27 : 485 517.
26. Alves NL, Arosa FA, van Lier RA. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol 2005 : 175 : 755 762.
27. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005 : 175 : 2261 2269.
28. Perez SA, Mahaira LG, Sotiropoulou PA et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol 2006 : 18 : 49 58.
29. Sivori S, Cantoni C, Parolini S et al. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol 2003 : 33 : 3439 3447.
30. Brady J, Hayakawa Y, Smyth MJ et al. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004 : 172 : 2048 2058.
31. Brandt K, Bulfone-Paus S, Jenckel A et al. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J Invest Dermatol 2003 : 121 : 1379 1382.
32. Brandt K, Bulfone-Paus S, Foster DC et al. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003 : 102 : 4090 4098.
33. Maeda M, Yanagawa Y, Iwabuchi K et al. IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells. Immunobiology 2007 : 212 : 537 547.
34. Pelletier M, Bouchard A, Girard D. In vivo and in vitro roles of IL-21 in inflammation. J Immunol 2004 : 173 : 7521 7530.
35. Ruckert R, Bulfone-Paus S, Brandt K. Interleukin-21 stimulates antigen uptake, protease activity, survival and induction of CD4+ T cell proliferation by murine macrophages. Clin Exp Immunol 2008 : 151 : 487 495.
36. Ugai S, Shimozato O, Kawamura K et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 2003 : 10 : 187 192. (Pubitemid 36348679)
37. Ma HL, Whitters MJ, Konz RF et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003 : 171 : 608 615.
38. Ugai S, Shimozato O, Yu L et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 2003 : 10 : 771 778.
39. Wang G, Tschoi M, Spolski R et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003 : 63 : 9016 9022.
40. Moroz A, Eppolito C, Li Q et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004 : 173 : 900 909.
41. Takaki R, Hayakawa Y, Nelson A et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 2005 : 175 : 2167 2173.
42. Nakano H, Kishida T, Asada H et al. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2006 : 8 : 90 9.
43. Sondergaard H, Frederiksen KS, Thygesen P et al. Interleukin 21 therapy increases the density of tumor infiltrating CD8(+) T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 2007.
44. Daga A, Orengo AM, Gangemi RM et al. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 2007 : 121 : 1756 1763.
45. Gelebart P, Zak Z, Anand M et al. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 2009.
46. Castermans K, Tabruyn SP, Zeng R et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008 : 112 : 4940 4947.
47. Smyth MJ, Wallace ME, Nutt SL et al. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005 : 201 : 1973 1985.
48. Smyth MJ, Teng MW, Sharkey J et al. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008 : 68 : 3019 3025.
49. Skak K, Kragh M, Hausman D et al. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008 : 7 : 231 240.
50. Skak K, Søndergaard H, Frederiksen KS, Ehrnrooth E. In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics. Cytokine 2009 : [Epub ahead of print].
51. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008 : 111 : 5326 5333.
52. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002 : 29 : 12 7.
53. Davis ID, Skrumsager BK, Cebon J et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007 : 13 : 3630 3636.
54. Thompson JA, Curti BD, Redman BG et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008 : 26 : 2034 2039.
55. Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009 : 15 : 2123 2129.
56. Ozaki K, Spolski R, Ettinger R et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 2004 : 173 : 5361 5371.
57. Vinuesa CG, Cook MC, Angelucci C et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005 : 435 : 452 458.
58. Herber D, Brown TP, Liang S et al. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007 : 178 : 3822 3830.
59. Bubier JA, Sproule TJ, Foreman O et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A 2009 : 106 : 1518 1523.
60. Sawalha AH, Kaufman KM, Kelly JA et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008 : 67 : 458 461.
61. Webb R, Merrill JT, Kelly JA et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009 : 60 : 2402 2407.
62. Mitoma H, Horiuchi T, Kimoto Y et al. Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 2005 : 16 : 609 615.
63. King C, Ilic A, Koelsch K et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004 : 117 : 265 277.
64. Yamanouchi J, Rainbow D, Serra P et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 2007 : 39 : 329 337.
65. Clough LE, Wang CJ, Schmidt EM et al. Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 2008 : 180 : 5393 5401.
66. Spolski R, Kashyap M, Robinson C et al. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A 2008 : 105 : 14028 14033.
67. Sutherland AP, Van BT, Wurster AL et al. Interleukin-21 is required for the development of type 1 diabetes in NOD mice. Diabetes 2009 : 58 : 1144 1155.
68. Todd JA, Walker NM, Cooper JD et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007 : 39 : 857 864.
69. Asano K, Ikegami H, Fujisawa T et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum Immunol 2007 : 68 : 384 391.
70. Young DA, Hegen M, Ma HL et al. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007 : 56 : 1152 1163.
71. Chen Q, Yang W, Gupta S et al. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor. Immunity 2008 : 29 : 899 911.
72. Jang E, Cho SH, Park H et al. A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+. J Immunol 2009 : 182 : 4649 4656.
73. Jungel A, Distler JH, Kurowska-Stolarska M et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004 : 50 : 1468 1476.
74. Li J, Shen W, Kong K et al. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006 : 64 : 515 522.
75. Andersson AK, Feldmann M, Brennan FM. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 2008 : 68 : 103 111.
76. Daha NA, Kurreeman FA, Marques RB et al. Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 2009 : 60 : 1255 1260.
77. Fantini MC, Rizzo A, Fina D et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007 : 37 : 3155 3163.
78. Fina D, Sarra M, Fantini MC et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008 : 134 : 1038 1048.
79. Monteleone G, Monteleone I, Fina D et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn′s disease. Gastroenterology 2005 : 128 : 687 694.
80. Caruso R, Fina D, Peluso I et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007 : 132 : 166 175.
81. Festen EA, Goyette P, Scott R et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009 : 58 : 799 804.
82. Vollmer TL, Liu R, Price M et al. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 2005 : 174 : 2696 2701.
83. Coquet JM, Chakravarti S, Smyth MJ et al. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J Immunol 2008 : 180 : 7097 7101.
84. Piao WH, Jee YH, Liu RL et al. IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis. Scand J Immunol 2008 : 67 : 37 46.
85. Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009 : 119 : 2052 2061.
86. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 2009 : 324 : 1569 1572.
87. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009 : 324 : 1572 1576.
88. Frohlich A, Kisielow J, Schmitz I et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009 : 324 : 1576 1580.